Who owns the vutrisiran patents, and what are they protecting?
Vutrisiran is a drug developed by Alnylam Pharmaceuticals and approved to treat certain hereditary transthyretin-mediated (hATTR) amyloidosis. Patents covering vutrisiran typically protect key parts of the therapy, such as the RNAi (small interfering RNA) composition, formulation/delivery (lipid nanoparticle aspects), and methods of use in specific diseases or patient populations. [1][2]
What is the main “patent” people mean for vutrisiran—composition, delivery, or method?
When people search “Alnylam vutrisiran patent,” they are often looking for one or more of these patent families:
- Composition of matter: claims tied to the drug’s siRNA sequences/chemistry and how the active ingredient is defined.
- Formulation/delivery: claims covering the lipid nanoparticle (or other delivery system) used to deliver the siRNA.
- Methods of treatment: claims tied to clinical use, such as treating hATTR amyloidosis in certain stages, genotypes, or patient settings.
Different families can have different expiration dates, and the earliest vs. latest expiration can differ by jurisdiction and claim set. [1][2]
When do Alnylam’s vutrisiran patents expire?
The exact expiration date depends on the specific patent document, jurisdiction, and whether exclusivity extensions apply. Patent expiration is not a single fixed date for “vutrisiran” overall; it varies by patent family and country. To determine the date for a specific claim family, you need the particular publication/patent number and its filing/priority dates in the country of interest. [1][2]
Are there separate patents for Vyndaqel/Vyndamax (tafamidis) vs. vutrisiran?
Yes. Vutrisiran is an RNAi therapy, while tafamidis (Vyndaqel/Vyndamax) is a different medicine with its own patent estate. Searches that compare “vutrisiran patent” with tafamidis usually turn into questions about how different therapies maintain exclusivity through different IP types (composition, methods, and regulatory exclusivity). [1][3]
What happens if a patent expires—do generic or biosimilar versions enter?
Because vutrisiran is a biologic-like RNAi product delivered via a specialized formulation, “generic” wording is often less direct than for small molecules. Competition is usually governed by whether another company can rely on different IP (e.g., different sequences, different delivery/formulation approaches) or enters only after key composition/formulation/method barriers and regulatory requirements are cleared. The exact pathway depends on the remaining patent claims and any regulatory exclusivities. [1][2]
Where can you find the actual patent numbers for “Alnylam vutrisiran”?
To get authoritative patent numbers and expiry timelines, you typically use patent databases and search by terms like:
- “vutrisiran”
- “Alnylam” plus “vutrisiran”
- the specific drug name used in the jurisdiction
Then match results by publication number, family, and jurisdiction. The most common way researchers do this is by starting from an entry that lists the relevant IP or regulatory dossier references and then following to specific patent publications. [1][2]
Sources
- https://www.drugs.com/vutrisiran.html
- https://patents.google.com/
- https://www.drugs.com/vyndaqel.html